Nkarta is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies to treat cancer. Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Sep 08, 2020
Aug 20, 2020
Jul 14, 2020
Nkarta Announces Closing of Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares